{"id":"W4389480655","doi":"10.1016/j.iotech.2023.100692","title":"LBA2 First-line (1L) durvalumab (D) + platinum-etoposide (EP) for patients (pts) with extensive-stage SCLC (ES-SCLC): Primary results from the phase IIIb LUMINANCE study","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Symphogen; Astellas Pharma; Gilead Sciences; Daiichi-Sankyo; Amgen; Pfizer; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Durvalumab; Internal medicine; Neutropenia; Gastroenterology; Etoposide; Cancer; Chemotherapy; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008755853,0.0002823187,0.000828456,0.0002259996,0.000157764,0.0005847388,0.0004086864,0.000280828,0.003050161],"category_scores_gemma":[0.0005554331,0.000165381,0.0005352491,0.0002516182,0.0002190054,0.000389199,0.0001855862,0.0009520729,0.0006350526],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007893299,"about_ca_system_score_gemma":0.0006569457,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001194951,"about_ca_topic_score_gemma":0.00584434,"domain_scores_codex":[0.9997864,0.0001075469,0.0000103084,0.00002986164,0.0000316668,0.00003422737],"domain_scores_gemma":[0.9997826,0.00003759245,0.0000554829,0.00002097231,0.0000150462,0.00008828175],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3677121,0.01702302,0.05628551,0.001767375,0.002113811,0.0003782281,0.0002721225,0.005351107,0.04696689,0.0005971396,0.02348013,0.4780526],"study_design_scores_gemma":[0.3400664,0.390466,0.2007678,0.0003013269,0.002802701,0.001976311,0.0002839977,0.00888904,0.01853353,0.0008029413,0.03502852,0.00008148329],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9860048,0.005467269,0.0004981833,0.0003668822,0.0000609735,0.000621688,0.002673457,0.0001468029,0.004160047],"genre_scores_gemma":[0.9900934,0.001651042,0.0007990863,0.000477647,0.00004470636,0.000386032,0.004104325,0.00002472451,0.002419042],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003050161,"threshold_uncertainty_score":0.01020378,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03270754885638696,"score_gpt":0.3655740603058458,"score_spread":0.3328665114494589,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}